Margüello, Miguel Santibañez
Garrastazu, Roberto
Ruiz-Nuñez, Mario
Helguera, Jose Manuel
Arenal, Sandra
Bonnardeux, Cristina
León, Carlos
Miravitlles, Marc
García-Rivero, Juan Luis
Article History
Received: 12 November 2015
Revised: 17 May 2016
Accepted: 6 June 2016
First Online: 8 September 2016
Competing interests
: J.L.G-R. reports receiving consulting and/or speaking fees from Almirall, Boehringer Ingelheim, Pfizer, Astra Zeneca, Chiesi, GlaxoSmithKline, Menarini, Takeda, Teva and Ferrer y Novartis; J.M.H. reports receiving speaking fees from GlaxoSmithKline, Boehringer, Novartis, Mundipharma and y Astra Zeneca; C.B. reports receiving speaking fees from GlaxoSmithKline, Boehringer, Ferrer, Astra Zeneca and Teva, y Chiesi; M.M. reports receiving consulting and/or speaking fees from Almirall, AstraZeneca, Boehringer Ingelheim, Ferrer Group, GlaxoSmithKline, Grifols, Esteve, Pfizer, Teva, Cipla, Novartis and Gebro Pharma y Takeda. The remaning authors declare no conflict of interest.